INT233296

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 1.90
Pain Relevance 0.19

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

methyltransferase activity (Mgmt) nucleus (Mgmt) DNA binding (Mgmt)
Anatomy Link Frequency
mononuclear cells 2
Mgmt (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Bioavailability 5 78.36 Quite High
Central nervous system 5 77.68 Quite High
Pain 1 71.00 Quite High
metalloproteinase 1 48.92 Quite Low
imagery 13 19.04 Low Low
anticonvulsant 10 5.00 Very Low Very Low Very Low
cva 5 5.00 Very Low Very Low Very Low
dexamethasone 4 5.00 Very Low Very Low Very Low
corticosteroid 3 5.00 Very Low Very Low Very Low
palliative 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 87 99.84 Very High Very High Very High
Glioma 57 94.56 High High
Recurrence 14 88.40 High High
Brain Tumor 20 87.92 High High
Toxicity 24 83.48 Quite High
Metastasis 42 81.28 Quite High
Oligodendroglioma 3 81.04 Quite High
Lung Cancer 9 76.32 Quite High
Non-small-cell Lung Cancer 21 75.28 Quite High
Breast Cancer 29 71.36 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Preliminary data suggest that prolonged dosing (up to 21 days) of temozolomide will significantly reduce MGMT activity in peripheral blood mononuclear cells (Tolcher et al 2003).
Negative_regulation (reduce) of MGMT in mononuclear cells
1) Confidence 0.57 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2387286 Disease Relevance 0.06 Pain Relevance 0
Based on studies by Tolcher et al. [16] showing that dose-dense regimens of temozolomide (including the alternating weekly regimen) deplete MGMT levels in peripheral blood mononuclear cells, it has been hypothesized that dose-dense temozolomide may deplete MGMT in tumor cells and increase antitumor activity.
Negative_regulation (deplete) of MGMT in mononuclear cells associated with cancer
2) Confidence 0.28 Published 2010 Journal Annals of Oncology Section Body Doc Link PMC2826096 Disease Relevance 1.21 Pain Relevance 0.12
Continuous daily dosing or “dose-dense” TMZ represents an attractive treatment approach based on in-vitro data demonstrating rapid MGMT enzyme depletion with continuous exposure to TMZ.72 A small Memorial Sloan-Kettering Cancer Center phase II trial evaluated continuous TMZ in recurrent malignant gliomas.
Negative_regulation (depletion) of MGMT enzyme associated with cancer and glioma
3) Confidence 0.07 Published 2010 Journal Core evidence Section Body Doc Link PMC2899776 Disease Relevance 0.63 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox